deaths were reported out of 120 000 S. aureus infections in 2017. The reasons for the higher rate of MRSA infection and its associated deaths are due to the rapid development of tolerance/resistance to multiple antibiotics drugs (multiple drug resistance, MDR), [5] and the quick adaptability of S. aureus to the host environment via evading the immune system and residing as a persister inside the host cells. Persisters are the cause of secondary and chronic infection with enhanced pathogenesis and resistance, therefore, MRSA persisters are known to be extremely difficult to treat with current antibiotics. [6] Based on these facts, it is conceivable that new resistance-free antibiotics or antistaphylococcal therapies are required not only to cure the lethal MDR MRSA infections but also to bypass the development and dissemination of antibiotic-resistance to avoid the future outbreak of MDR bacterial pathogen infectious disease. [7] In this context, various antistaphylococcal strategies such as antimicrobial peptides (AMPs), [8] enzybiotics, [9] antivirulence agents, [10] gene editing enzymes, [11] bacteriophages, [12] and nanoparticles (NPs) [13,14] are being developed as alternative therapeutic options to antibiotics. Although AMPs, antivirulence agents, or bacteriophages have produced promising results as therapeutic agents yet the development of resistance against Methicillin-resistant Staphylococcus aureus (MRSA) causes diseases ranging from skin infections to lethal sepsis and has become a serious threat to human health due to multiple-drug resistance (MDR). Therefore, a resistance-free antibacterial therapy is necessary to overcome MDR MRSA infections. In this study, an antibacterial nanorobot (Ab-nanobot) is developed wherein a cell wall-binding domain (CBD)-endolysin, acting as a sensor, is covalently conjugated with an actuator consisting of an iron oxide/silica core-shell. The CBD-endolysin sensor shows an excellent specificity to detect, bind, and accumulate on the S. aureus USA300 cell surface even in a bacterial consortium, and in host cell infections. Ab-nanobot specifically captures and kills MRSA in response to medically approved radiofrequency (RF) electromagnetic stimulation (EMS) signal. When Ab-nanobot receives the RF-EMS signal on the cell surface, actuator induces cell death in MRSA with 99.999% removal within 20 min by cell-wall damage via generation of localized heat and reactive oxygen species. The in vivo efficacy of Ab-nanobot is proven using a mice subcutaneous skin infection model. Collectively, this study offers a nanomedical resistance-free strategy to overcome MDR MRSA infections by providing a highly specific nanorobot for S. aureus.